Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rival Novo. Ricks spoke with CNBC in front of the roughly 240 acres of land that will eventually host Lilly's new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. The company on Monday broke ground on the upcoming site nearly a year after first announcing it, and said it expects the plant to be operational by 2030. The facility will most notably produce Lilly's closely watched GLP-1 pill for obesity, Foundayo, which entered the U.S. market in April.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.